Navigation LinksTop Biology NewsTop Medical NewsTop Biology TechnologyTop Medical Technology

Biology Technology

Australian Discovered Biomarkers Map Path to New Blood Test for Bowel Cancer

5/20/2012

0

GOOD
SAN DIEGO, May 20, 2012 A team of Australian scientists has identified new genes that show identifiable changes in the blood of people with bowel cancer. The discovery has the potential to underpin a new cost-effective blood test that would signal the early stages of bowel cancer. This test could potentially save thousands of lives by supplementing existing screening programs a... [Comments]

Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities

5/18/2012

0

GOOD
HACKENSACK, N.J., May 18, 2012 Champions Oncology Inc. (OTC: CSBR) announced today that it has received U.S. Clinical Laboratory Improvement Amendment (CLIA) certification from the Maryland Department of Health and Mental Hygiene Office of Health Care Quality required for the company to conduct medical laboratory tests. The Company's President, Ronnie Morris, MD commented, "Ob... [Comments]

Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference

5/18/2012

0

GOOD
NEW YORK, May 18, 2012  Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. Daniel G. Chain, the company's chairman and CEO, will be presenting at the Seventh Annual Neurotech Investing and Partnering Conference. (Logo:  http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ) The title of Dr. Chain's presentation is "Prefibrillar Tau Neoepitopes Offer A... [Comments]

Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets

5/18/2012

0

GOOD
SAN DIEGO, May 18, 2012 Sequenom, Inc. (NASDAQ: SQNM ), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication from the large Women & Infants multi-center clinical study on the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) has been published online in the pee... [Comments]

New Competitive Arena Emerges for Pharmaceutical Companies in Healthcare's Changing Payment Landscape, Finds PwC Health Research Institute Study

5/17/2012

0

GOOD
NEW YORK, May 17, 2012   Pharmaceutical companies that are first to meet healthcare's new expectations of value could have an advantage in the competition for market share and brand differentiation, according to a report published today by the Health Research Institute (HRI) at PwC US.  Physicians, health insurers and patients now want to know how well a drug will work... [Comments]

Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets

5/17/2012

0

GOOD
DALLAS, May 17, 2012 The " Anesthesia Drugs Market (2011 - 2015) - U.S. Market Entry Study " analyzes and studies the U.S. market for intravenous anesthesia drugs with special focus on ketamine, distribution structure of anesthesia drugs in U.S., potential buyers, export & import system for controlled substances in U.S. and U.S. market entry strategy. Browse marke... [Comments]

Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway

5/17/2012

0

GOOD
BALTIMORE, May 16, 2012  In an effort to voice concern on biosimilars pathways for patients with primary immunodeficiency diseases (PIDD), the Immune Deficiency Foundation (IDF) offered oral testimony at last week's U.S. Food and Drug Administration (FDA) public hearing on draft guidance of biosimilars products. IDF urged the FDA to exempt immunoglobulin (Ig) therapies from... [Comments]

Sigma-Aldrich Corporation Announces New Credit Facility

5/16/2012

0

GOOD
ST. LOUIS, May 16, 2012  Sigma-Aldrich announced today that it has established a new $600 million revolving credit facility that will mature on May 10, 2017.  The new facility replaces a $450 million revolving credit facility that was scheduled to mature on December 11, 2012.  The $600 million facility will provide back-up liquidity for the commercial paper program... [Comments]

People with paralysis control robotic arms to reach and grasp using brain computer interface

5/16/2012

0

GOOD
 [Providence, R.I.] -- On April 12, 2011, nearly fifteen years after she became paralyzed and unable to speak, a woman controlled a robotic arm by thinking about moving her arm and hand to lift a bottle of coffee to her mouth and take a drink. That achievement is one of the advances in brain-comp... [Comments]People with paralysis control robotic arms to reach and grasp using brain computer interface

Paralyzed individuals use thought-controlled robotic arm to reach and grasp

5/16/2012

0

GOOD
 In an ongoing clinical trial, a paralyzed woman was able to reach for and sip from a drink on her own for the first time in nearly 15 years by using her thoughts to direct a robotic arm. The trial, funded in part by the National Institutes of Health, is evaluating the safety and feasibili... [Comments]Paralyzed individuals use thought-controlled robotic arm to reach and grasp

UV Flu Technologies to Commence a National TV Advertising Campaign

5/16/2012

0

GOOD
CENTERVILLE, Mass., May 16, 2012  UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that it has signed a television joint venture agreement with Stardust  International TV, of San Bernardino Ca., for the filming of a 60 second commercial, along with a 10 minute, "mini-infomercial." The commercial will run locally, regionally, and nationally... [Comments]

Medicine Technology

First, do no harm: Study finds danger in standard treatment for a serious lung disease

5/20/2012

0

GOOD
ANN ARBOR, Mich., May 20, 2012 A combination of three drugs used worldwide as the standard of care for a serious lung disease puts patients in danger of death or hospitalization, and should not be used together to treat the disease, called idiopathic pulmonary fibrosis, according to the surprising results of a rigorous independent study. The study, which will appear o... [Comments]

Medical Device Developers - Network at MD&M East Next Week

5/18/2012

0

GOOD
PHILADELPHIA, Pennsylvania, May 18, 2012 This is your last week to pre-register for MD&M East, providing Medical Device Developers direct access to   Hundreds of Suppliers ,   Educational Opportunities , and   Exclusive Industry Events,     all in   One Convenient Location.     Qualified members of the medtech community c... [Comments]

Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference

5/18/2012

0

GOOD
PARSIPPANY, N.J., May 18, 2012  Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference on Wednesday, May 30, 2012 at 4:00P... [Comments]

Denton Vacuum's New Website Organizes Thin-Film Technology Information By Industry

5/18/2012

0

GOOD
MOORESTOWN, N.J., May 18, 2012 /PRNewswire-iReach/ -- Denton Vacuum LLC, a leading supplier of production-scale thin-film technology systems, today launched a new website that guides visitors to information tailored specifically to their industry needs. "The site's organization and navigation mirror what it's like to work with our company: Denton is efficient, organized, and understands your... [Comments]

Sensus Healthcare and Texas Dermatology Associates at Baylor University Medical Center Announce the Formation of the SRT University™ Comprehensive Education Series for Practitioners, Healthcare Professionals, and Patients

5/18/2012

0

GOOD
BOCA RATON, Fla., May 18, 2012   Sensus Healthcare and Texas Dermatology Associates at Baylor University Medical Center of Dallas, TX are proud to announce the establishment of the SRT University™ Comprehensive Education Series for practitioners, healthcare professionals, and patients. SRT University™ will offer multi-tiered education and training curriculums for... [Comments]

Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules

5/18/2012

0

GOOD
ALLEGAN, Mich., May 18, 2012  Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Lansoprazole capsules (15 mg). Shipments of product to customers have already begun.  (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ) Thi... [Comments]

Richard Wolf Medical Instruments introduces groundbreaking 5514 Endocam Performance HD

5/18/2012

0

GOOD
VERNON HILLS, Ill., May 18, 2012  Surgeons using endoscopy to stalk pathology know that sharper views enhance treatments and improve patients' outcomes. But until now, high-definition endocams have been too expensive for many physicians in private offices or ambulatory surgery centers. (Logo: http://photos.prnewswire.com/prnh/20120426/CG95191LOGO ) Richard Wolf Medical... [Comments]

Consumers Are Advised to Be Aware of Hidden Costs in Some Discount Dental Plans

5/18/2012

0

GOOD
SAN DIEGO, Calif., May 18, 2012  Not all discount dental plans are created equal, according to Dr. Michael Grossman, President and CEO at First Dental Health . Unexpected fees totaling hundreds of dollars are common and can take consumers by surprise. In addition, some discount dental plan specialists' fee discounts are very limited and difficult to verify, and not all plan... [Comments]

Digestive Care, Inc. Announces FDA Approval of PERTZYE™ (pancrelipase) Delayed-Release Capsules

5/18/2012

0

GOOD
BETHLEHEM, Pa., May 18, 2012  Digestive Care, Inc. (DCI), announced that the company has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for PERTZYE™, indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF) or other conditions.     PERTZYE is a unique pancreatic enzym... [Comments]

Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®

5/18/2012

0

GOOD
NATICK, Mass., May 18, 2012 Boston Scientific Corporation (NYSE: BSX ) announces that seven abstracts and additional clinical data analyses will be presented at Digestive Disease Week ® (DDW), May 19 – 22 in San Diego.  The analyses involve the SpyGlass ® Direct Visualization System, WallFlex® Biliary RX Stent, Expect™ 19 Flex Endoscopic Ultras... [Comments]

Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)

5/18/2012

0

GOOD
SAN DIEGO, May 18, 2012  Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa™ (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a c... [Comments]

(Date:5/20/2012)... team of Australian scientists has identified new genes that show ... The discovery has the potential to underpin a ... of bowel cancer. This test could potentially save thousands of ... risk to have a colonoscopy. The research[1] - ... medical conference in the United States - is the result ...
(Date:5/18/2012)... 2012 Champions Oncology Inc. (OTC: CSBR) ... Laboratory Improvement Amendment (CLIA) certification from the Maryland ... Health Care Quality required for the company to ... Company,s President, Ronnie Morris, MD commented, "Obtaining CLIA ... This approval validates the quality of our laboratory, ...
(Date:5/18/2012)... 2012  Intellect Neurosciences, Inc. (OTCPK: ILNS) announces ... and CEO, will be presenting at the Seventh ... (Logo:  http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ) The ... Neoepitopes Offer Attractive Targets for Active and Passive ... 21st at the Intercontinental Hotel in Boston from ...
(Date:5/18/2012)... Inc. (NASDAQ: SQNM ), a life sciences ... a new publication from the large Women & Infants ... Medicine,s (Sequenom CMM) MaterniT21 PLUS laboratory-developed test ... Prenatal Diagnosis . Along with this week,s publication, ... May 12, 2012, Sequenom CMM has processed more than ...
Breaking Biology Technology:Australian Discovered Biomarkers Map Path to New Blood Test for Bowel Cancer 2Australian Discovered Biomarkers Map Path to New Blood Test for Bowel Cancer 3Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 2Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 3Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 2Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 3Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 2Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 3Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 4Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 5
... Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) announced ... I,Study to Evaluate Systemic Wild-Type Reovirus (REOLYSIN(R)) ... Malignancies" will be available in,the November/December issue ... of the International Society for Biological Therapy ...
... MedImmune today announced,that researchers will present eight posters ... of the American College of Rheumatology, from,October 24 ... San Francisco, California., "MedImmune is working on ... systemic autoimmune rheumatic diseases," said Barbara,White, M.D., vice ...
... Commercial Exhibit Draws More Than 2,500 Conference Attendees, ... inventor,of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low ... and objective clinical,studies presented at the American Society ... 19-21, 2008, found Masimo SET(R) and,Masimo Rainbow SET(R) ...
Other Biology Technology:Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 3MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 2MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 3New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 2New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 3New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 4New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 5New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 6New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 7New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 8
(Date:5/18/2012)...  Perrigo Company (Nasdaq: PRGO;TASE) today announced that ... Food and Drug Administration for its abbreviated new ... Shipments of product to customers have already begun.  ... This new product for the U.S. ... 24HR capsules (15 mg) and is indicated for ...
(Date:5/18/2012)... -- Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused ... to treat gastrointestinal and liver diseases, announced today ... Zysa™ (spherical carbon adsorbent, formerly AST-120) for the ... affecting 10-15% of the Western world.  Zysa is ... and countries that recognize the CE Mark. Ocera is ...
(Date:5/18/2012)... 18, 2012 Generex Biotechnology Corporation (OTCBB: ... the Scientific Advisory Board (SAB) of its wholly-owned ... breast cancer vaccine.  The following distinguished scientists, scholars, ... FACP (University of Texas MD Anderson Cancer Center), ... of Medicine Melvin and Bren Simon Cancer Center), ...
Breaking Medicine Technology:Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules 2Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d) 2Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d) 3Generex Augments Antigen Express Scientific Advisory Board 2Generex Augments Antigen Express Scientific Advisory Board 3Generex Augments Antigen Express Scientific Advisory Board 4Missing Gene Tied to Bone Marrow Transplant Problems 61889 1Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 10851 1Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 10851 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 10851 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 10851 4Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 61886 1Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 61886 2Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 61886 3